Vanguard Capital Management
ABOS icon

Vanguard Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Vanguard Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.03M Buy
1,816,442
+144,370
+9% +$373K ﹤0.01% 3149
2026
Q2 		$4.46M Buy
1,672,072
+165,795
+11% +$410K ﹤0.01% 3168
2026
Q1 		$3.55M Buy
+1,506,277
New +$3.84M ﹤0.01% 3183

Other funds holding ABOS

Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Knollwood Investment Advisory
Knollwood Investment Advisory Hunt Valley, Maryland $1.18B AUM 37.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $36.2B AUM 20.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Capital Management's ABOS Position: Q3 2026 in Review

Vanguard Capital Management increased its Acumen Pharmaceuticals (ABOS) stake by 8.6% in Q3 2026, buying an estimated $373K and bringing the position to 1,816,442 shares worth $4.03M. The position accounts for ﹤0.01% of the portfolio, ranked #3149.

Vanguard Capital Management first reported a position in ABOS in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.46M in Q2 2026. 67 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

  • Vanguard Capital Management held 1,816,442 shares of Acumen Pharmaceuticals worth $4.03M as of Q3 2026.
  • Vanguard Capital Management bought 144,370 Acumen Pharmaceuticals shares in Q3 2026, an estimated $373K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3149 holding.
  • Vanguard Capital Management first reported a position in Acumen Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Acumen Pharmaceuticals position peaked at $4.46M in Q2 2026.
  • 67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.